Genetic polymorphisms of nerve growth factor receptor (NGFR) and the risk of Alzheimer's disease

Hui-Chi Cheng1, Yu Sun2, Liang-Chuan Lai3, Shih-Yuan Chen1, Wen-Chung Lee1,4,5, Jen-Hau Chen1,6, Tai-Fu Chen7, Hua-Hsiang Chen1, Li-Li Wen8, Ping-Keung Yip9, Yi-Min Chu10, Wei J Chen1,4,5 and Yen-Ching Chen1,4,5*

Abstract

Background: Loss of basal forebrain cholinergic neurons is attributable to the proapoptotic signaling induced by nerve growth factor receptor (NGFR) and may link to Alzheimer's disease (AD) risk. Only one study has investigated the association between NGFR polymorphisms and the risk of AD in an Italian population. Type 2 diabetes mellitus (DM) may modify this association based on previous animal and epidemiologic studies.

Methods: This was a case-control study in a Chinese population. A total of 264 AD patients were recruited from three teaching hospitals between 2007 to 2010; 389 controls were recruited from elderly health checkup and volunteers of the hospital during the same period of time. Five common (frequency ≥ 5%) haplotype-tagging single nucleotide polymorphisms (htSNPs) were selected from NGFR to test the association between NGFR htSNPs and the risk of AD.

Results: Variant NGFR rs734194 was significantly associated with a decreased risk of AD [GG vs. TT copies: adjusted odds ratio (OR) = 0.43, 95% confidence interval (CI) = 0.20-0.95]. Seven common haplotypes were identified. Minor haplotype GCGCG was significantly associated with a decreased risk of AD (2 vs. 0 copies: adjusted OR = 0.39, 95% CI = 0.17-0.91). Type 2 DM significantly modified the association between rs2072446, rs741072, and haplotype GCTTG and GTTCG on the risk of AD among ApoE ε4 non-carriers (Pinteraction < 0.05).

Conclusion: Inherited polymorphisms of NGFR were associated with the risk of AD; results were not significant after correction for multiple tests. This association was further modified by the status of type 2 DM.

Keywords: NGFR, Alzheimer's disease, htSNP, haplotype

Introduction

Dementia is a degenerative brain syndrome characterized by decline or loss in cognitive function [1]. About 30 million elders suffered from dementia worldwide in 2008 estimated by Alzheimer’s Disease International. Alzheimer's disease (AD) is the most common causes of dementia and was the fifth leading cause of death for those aged 65 or older in the United States in 2006 [1]. In Taiwan, more than 160,000 people were demented in 2009 [2] and the number of AD patients keeps raising in many aging populations.

Degeneration of basal forebrain cholinergic neurons (BFCN) has shown to modulate cognitive function in AD patients [3,4]. Nerve growth factor receptor (NGFR, also called p75NTR) is one of the receptors of NGF and is expressed at the end of cholinergic axon [5,6]. The gene encoding NGFR is located on chromosome 17q21-q22. In normal brain, NGFR regulates tyrosine kinase receptor type 1 (TrkA), another receptor of NGF, and induces the signaling of neuronal cell survival [7,8]. In contrast, in AD brain, NGFR acts as a proapoptotic receptor in neuron cell death via binding to amyloid-beta (Aβ), NGF, or proNGF [9,10]. As a whole, NGFR plays multiple roles (survival and apoptosis) in human brain, dependent on the cellular context.
So far, only one study assessed the association between \textit{NGFR} genetic polymorphisms and the risk of AD in an Italian population [11]. Cozza et al. found that variant rs2072446 was associated with a significantly decreased risk of familial AD [additive model: odds ratio (OR) = 0.28] [11]. However, no association was observed for other \textit{NGFR} SNPs (rs741072, rs2072446, rs2072445, and rs734194) and the risk of sporadic AD [11]. In addition, type 2 DM has been related to the change of \textit{NGFR} expression in rat brain [12] and cognitive impairment and dementia in the elderly [13-15]. However, no study has explored how type 2 DM affects the association of \textit{NGFR} polymorphisms with the risk of AD.

\textit{NGFR} plays an important role in neuronal survival and apoptosis, which may be related to AD pathogenesis. However, only one study explored the association between sequence variants of \textit{NGFR} and AD in a Caucasian population. Therefore, we hypothesized that \textit{NGFR} genetic polymorphisms were associated with the risk of AD in Chinese population. In addition, \textit{NGFR} may involve in diabetic encephalopathy through neuronal apoptosis. Therefore, this study further investigated how type 2 DM modified the association of \textit{NGFR} genetic polymorphisms with the risk of AD.

Materials and methods

Study Population

This was a case-control study. A total of 295 sporadic AD patients were recruited from neurology clinic of three teaching hospitals in northern Taiwan from 2007 to 2010. Healthy controls (n = 406) were recruited from elderly health checkup and volunteers during the same period of time. All participants were Chinese aged 60 years or older. Participants with the following diseases were excluded: hemorrhagic stroke, organic brain tumor, central nervous system diseases (e.g., Parkinson’s disease), depression, cerebral infarction, and dementia other than AD (e.g., vascular dementia and mixed-type dementia, etc.). This study was approved by the institutional review board of each hospital and College of Public Health, National Taiwan University. Written informed consent was obtained from each study participant. The consent from the legal guardian/next of kin was obtained when patients had serious cognitive impairment.

A questionnaire was administered to collect information on demography, comorbidity (e.g., DM and stroke), life style (e.g., cigarette smoking, alcohol, tea or coffee consumption, and exercise); and family history. Blood sample was collected in a tube containing EDTA from each participant. Genomic DNA was extracted by using tagSNP program [23]. A total of 5 htSNPs (rs2072445, rs2072446, rs734194, rs741072, and rs741073) with an \(r^2\) of 0.87 were selected in \textit{NGFR} gene by tagSNP program [20] (Table 1). Five SNPs spanning \textit{NGFR} formed one block.

Genotypes of \textit{NGFR} and Apolipoprotein E (\textit{ApoE ε4}) SNPs (rs429358 and rs7412) were determined by TaqMan® Genomic Assays [24] using ABI 7900 HT fast real-time PCR system (Applied Biosystems, CA, USA). Genotyping success rate was greater than 95% for each SNP. Duplicate of 5% internal samples were selected for quality control purpose and the concordance rate reached 100% for each SNP.

Statistical Analyses

Comparison of demographic characteristics between cases and controls were examined by using Student’s t tests for normally-distributed continuous variables and chi-square tests for categorical variables.

Hardy-Weinberg equilibrium (HWE) test was performed for each SNP among controls to check genotyping error and selection bias. Partition-ligation-expectation-maximization algorithm was utilized to estimate haplotype frequencies by using tagSNP program [23].

To control for the confounding effect of age, frequency matching was used to match cases and controls on age within an interval of 5 years. The multivariate
Table 1 Characteristics of the study population

|                        | Alzheimer's disease (n = 264) | Controls (n = 389) |
|------------------------|-----------------------------|------------------|
| Age (years)            | 79 ± 7                      | 73 ± 6           |
| Female                 | 172 (65%)                   | 207 (53%)        |
| Education              |                             |                  |
| Elementary             | 132 (50%)                   | 40 (10%)         |
| High school            | 93 (35%)                    | 160 (41%)        |
| College and above      | 39 (15%)                    | 189 (49%)        |
| Cigarette smoking      |                             |                  |
| Never                  | 204 (77%)                   | 321 (83%)        |
| Former                 | 42 (16%)                    | 56 (14%)         |
| Current                | 18 (7%)                     | 12 (3%)          |
| Alcohol consumption    |                             |                  |
| Never                  | 230 (87%)                   | 349 (90%)        |
| Former                 | 24 (9%)                     | 13 (3%)          |
| Current                | 10 (4%)                     | 27 (7%)          |
| Type 2 diabetes        | 48 (18%)                    | 51 (13%)         |
| Hypertension           | 103 (39%)                   | 205 (53%)        |
| Hyperlipidemia         | 48 (18%)                    | 115 (30%)        |
| ApoE ε4 carriers       | 107 (40%)                   | 55 (14%)         |

Abbreviation: ApoE, Apolipoprotein E gene; SD, standard deviation.

Results

Characteristics of study population

A total of 264 AD cases and 389 controls were recruited in this study. As compared with controls, AD cases were older (79 vs. 72 years old), included more women (65% vs. 53%), had a lower education level (elementary school: 50 vs. 10 years), more with the history of type 2 DM (18% vs. 13%), fewer with the history of hypertension (39% vs. 53%) or hyperlipidemia (18% vs. 30%), and more were ApoE ε4 carriers (40% vs. 14%, Table 1).

Haplotype-tagging SNPs in NGFR

Five htSNPs were selected from 11 common (frequency ≥5%) SNPs spanning NGFR formed one block, which was determined by the modified Gabriel et al. algorithm [21,22] (Figure 1). None of the NFGR SNPs was out of HWE (Table 2). The internal quality-control specimens did not show evidence of genotyping error as well. The minor allele frequencies (MAFs) of rs734194 (0.19 vs. 0.29) and rs741072 (0.41 vs. 0.30) were slightly different between HapMap data and our controls. Other SNPs (rs2072445 and rs2072446) showed similar frequencies.

NGFR SNPs and AD risk

Variant rs734194 was significantly associated with a decreased risk of AD (GG vs. TT: OR = 0.43, 95% CI = 0.20-0.95) (Table 3). rs734194 remained significantly associated with an increased risk of AD under the assumption of additive model (OR = 0.71, 95% CI = 0.52-0.98, data not shown). After controlling for FDR, no significant association was observed for NGFR SNPs and the risk of AD.

NGFR haplotypes and AD risk

Seven common (frequency≥5%) haplotypes, composed by 5 htSNPs, were identified with a cumulative frequency of 97.3% in controls (Figure 1 & Table 4). Figure 1 demonstrated the LD structure by using the genotype data of controls in this study. The global P for the association between haplotypes and the risk of AD was 0.27. Participants carrying two copies of the minor Hap1 GCGCG had a significantly decreased risk of AD (OR = 0.39, 95% CI = 0.17-0.91). No haplotype was associated with AD risk under the assumption of additive model (data not shown). After correction for multiple tests by using FDR, significant association between NGFR polymorphisms and AD risk did not retain.

Effect of ApoE ε4 status

The ApoE ε4 carriers had a significantly increased risk of AD (OR = 4.45, 95% CI = 2.93-6.75) after adjusting for age and sex. The significant association remained after stratified by sex (male: OR = 3.45, 95% CI = 1.82-6.56;
female: OR = 6.00, 95% CI = 3.38-10.62, data not shown).

**Effect modification by vascular risk factors**

Among the vascular risk factors (hypertension, type 2 DM, and hyperlipidemia), type 2 DM was the only factor significantly modifying the association between NGFR polymorphisms (rs2072446, rs741072, Hap2, and Hap5) and the risk of AD. After stratification by type 2 DM status, significant associations were observed in some subgroups. Because ApoE ε4 status is an important risk factor for AD, we assess the effect modification by type 2 DM for ApoE ε4 carriers and non-carriers separately.

For NGFR SNPs, in ApoE ε4 non-carriers without type 2 DM, variant rs2072446 was associated with an increased risk of AD (TT+TC vs. CC: OR = 2.18, 95% CI = 1.19-4.00) (Table 5). In contrast, variant rs734194 was associated with a decreased risk of AD (OR = 0.28, 95% CI = 0.08-0.98, Table 5) among diabetic ApoE ε4 non-carriers. Significant interactions were observed between type 2 DM and NGFR rs2072446 and rs741072 on the risk of AD among ApoE ε4 non-carriers (P\_	ext{interaction} = 0.007 and 0.04, Table 5). Except the interaction between type 2 DM and NGFR rs2072446 among ApoE ε4 non-carriers, other results were not significant after controlling for FDR.

For NGFR haplotypes, among ApoE ε4 non-carriers, diabetic patients carrying minor Hap1 GCGCG had a decreased risk of AD (1 or 2 copies vs. 0 copies: OR = 0.28, 95% CI = 0.08-0.97, Table 6). In addition, among ApoE ε4 non-carriers, non-diabetic patients carrying minor Hap5 GTTGG were associated with a 2.12-fold increased risk of AD (95% CI = 1.13-3.99, Table 6). Among ApoE ε4 non-carriers, type 2 DM significantly modified the association of Hap2 and Hap5 with AD risk.

---

**Table 2 Characteristics of NGFR haplotype-tagging SNPs**

| SNP1   | SNP2   | SNP3   | SNP4   | SNP5   |
|--------|--------|--------|--------|--------|
| rs2072445 | rs2072446 | rs734194 | rs741072 | rs741073 |
| G→T    | C→T    | T→G    | C→T    | G→A    |

| Location | HapMap CHB | Controls | Cases |
|----------|------------|----------|-------|
| Intron   | MAF        | MAF      | MAF   |
| Exon     | 0.09       | 0.07     | 0.08  |
| 3'UTR    | 0.15       | 0.11     | 0.11  |
| 3'UTR    | 0.19       | 0.29     | 0.25  |
| 3'UTR    | 0.41       | 0.30     | 0.34  |
| 3'UTR    | 0.25       | 0.24     | 0.25  |

| Abbreviations: HWE, Hardy-Weinberg equilibrium; UTR, untranslated region; MAF, minor allele frequency; CHB, Han Chinese in Beijing. |
Table 3 NGFR SNPs and the risk of Alzheimer’s

| SNP      | 0 copies | 1 copy | 2 copies |
|----------|----------|--------|----------|
|          | Case/control OR | Case/control OR (95% CI) | p | Case/control OR (95% CI) | p |
| rs2072445 | 223/337 | 1.00 | 41/48 | 1.31 (0.76-2.28) | 0.98 | 0/4 | NA |
| rs2072446 | 208/306 | 1.00 | 52/79 | 1.43 (0.86-2.37) | 0.60 | 4/4 | 3.32 (0.65-16.85) | 0.22 |
| rs734194  | 146/196 | 1.00 | 103/160 | 0.79 (0.52-1.20) | 0.48 | 15/33 | 0.43 (0.20-0.95) | 0.06 |
| rs741072  | 110/157 | 1.00 | 118/192 | 1.02 (0.67-1.56) | 0.67 | 36/40 | 1.10 (0.59-2.06) | 0.64 |
| rs741073  | 145/222 | 1.00 | 105/151 | 1.04 (0.69-1.57) | 0.26 | 14/16 | 2.04 (0.82-5.09) | 0.13 |

All models were adjusted for age, sex, education, and ApoE ε4 status.
Abbreviations: OR, odds ratio; CI, confidence interval; NA, not applicable.

(P\text{interaction} = 0.04 and 0.01, Table 6). Results were not significant after controlling for FDR.

Discussion

This is the first study exploring the association between NGFR polymorphisms and the risk of AD by using 5 htSNPs. We found that NGFR rs734194 was significantly associated with a decreased risk of AD, but this was not observed in the only previous study in an Italian population [11]. Possible reasons for the inconsistent findings between the Italian study [11] and ours include differences in sample size (Cozza et al. vs. ours, sporadic AD: 151 vs. 264, controls: 97 vs. 389), case selection (not available vs. incident cases), race (Italian vs. Chinese), study time period (not available vs. 2007 to 2010), mean age (AD: 65 vs. 79, controls: 64 vs. 73), and SNPs selected (4 functional SNPs vs. 5 htSNPs). This is also the only Asian study up to date. In addition, no significant association was observed for NGFR rs2072445 (in intron), rs2072446 (in exon), and rs741072 [in 3’ untranslated region (UTR)], which is consistent with the findings of the Italian study [11]. rs741073 has not been explored for AD risk previously and was not associated with AD risk in our study. Although 5 htSNPs are in strong linkage disequilibrium (LD; i.e., high pairwise D’ as shown in dark gray, Figure 1) and located within the same haplotype block, the pairwise correlation (r^2) between rs734194 (SNP3) and any other SNP is quite low (SNP1: 0.02, SNP2: 0.04, SNP4: 0.20, SNP5: 0.10, Figure 1).

Cholinergic hypothesis [3,4] has been used to elucidate the role of NGFR in AD pathogenesis because of selective loss of BFCN observed in AD patients. That is, elevated expression of NGFR and decreased TrkA may activate neuron apoptosis [29,30]. In addition, the binding of Aβ [31-33] and proNGF [9,34] to NGFR also induce neuron apoptosis. rs734194 is located on 3’ UTR and thus plays an important role in regulating the mRNA stability and translational efficiency. Therefore, variations in rs734194 may reduce the expression of NGFR or the binding of NGF, Aβ, or proNGF to NGFR, which inactivates the neuron apoptotic signaling and leads to decreased risk of AD. It is also possible that the variations of rs734194 decrease the secretion of NGFR on BFCN and thus reduce the interaction of NGFR with Aβ and proNGF, which lower the neurotoxicity and apoptosis of BFCN. All together, these mechanisms may explain the protective effect of NGFR rs734194 on the risk of AD observed in this study.

Table 4 NGFR haplotypes and the risk of Alzheimer’s disease

| Haplotype | Frequency among controls (%) | Co-dominant model |
|-----------|-----------------------------|-------------------|
|           | Case/control OR | Case/control OR (95% CI) | p | Case/control OR (95% CI) | p |
| Hap1: GCGCG | 27.8 | 148/203 | 1.00 | 105/156 | 0.82 (0.54-1.25) | 0.36 | 1/30 | 0.39 (0.17-0.91) | 0.03 |
| Hap2: GCTTG | 21.9 | 159/234 | 1.00 | 90/140 | 0.94 (0.61-1.47) | 0.79 | 15/15 | 1.01 (0.42-2.42) | 0.99 |
| Hap3: GCTTA | 11.5 | 205/305 | 1.00 | 56/78 | 1.09 (0.65-1.84) | 0.74 | 3/6 | 1.38 (0.27-6.97) | 0.70 |
| Hap4: GCTCA | 11.3 | 197/304 | 1.00 | 65/81 | 1.37 (0.83-2.27) | 0.22 | 2/4 | 0.94 (0.11-7.94) | 0.95 |
| Hap5: GTTCG | 10.3 | 213/312 | 1.00 | 47/74 | 1.37 (0.81-2.33) | 0.23 | 4/3 | 3.59 (0.66-19.42) | 0.14 |
| Hap6: GCTCG | 8.9 | 217/323 | 1.00 | 46/63 | 0.97 (0.54-1.73) | 0.92 | 1/3 | 0.18 (0.01-5.26) | 0.32 |
| Hap7: TCTCG | 5.6 | 230/347 | 1.00 | 34/40 | 1.15 (0.63-2.12) | 0.65 | 0/2 | NA |

Global test P = 0.27

All models were adjusted for age, sex, education, and ApoE ε4 status.
Global test was testing for the null hypothesis that none of the haplotype was associated with AD risk.
Abbreviations: OR, odds ratio; CI, confidence interval; NA, not applicable.
We found that Hap1 GCGCG was significantly associated with a decreased risk of AD. rs734194 is the only SNP carrying the variant allele in Hap1. Therefore, the significant association of Hap1 and AD may be attributable to rs734194. It is also possible that other rare polymorphisms not analyzed here are responsible for the association observed. Our finding was not comparable to the Italian study [11] because fewer SNPs were selected and no significant association was observed for NGFR haplotypes in that study.

This study found that type 2 DM significantly modified the association between NGFR polymorphisms and the risk of AD in ApoE ε4 non-carriers. It is possible that type 2 DM modifies the association between NGFR and AD via the following mechanisms: (1) hyperglycemia [35-37], (2) altered insulin level and sensitivity in the brain [13,38-40], and (3) diabetes-related vascular diseases, e.g., hypertension and arterial disease [41]. In addition, ApoE ε4 status affects cholesterol metabolism and may act together with DM to modulate the risk of AD [42-44]. The significant effect modification was only observed in ApoE ε4 non-carriers, which may be due to the counteracting effect between ApoE ε4 allele (increase AD risk) and variant of NGFR (protective effect) on AD risk.

This study has some strengths. No study has investigated the role of NGFR polymorphisms on the risk of Alzheimer's disease stratified by ApoE ε4 status.
Table 6 Effect modification by type 2 diabetes on the association between NGFR haplotypes and the risk of Alzheimer’s disease stratified by ApoE ε4 status

| ApoE ε4 non-carriers | NGFR variant non-carriers | NGFR variant carriers | P<sub>interaction</sub> |
|----------------------|---------------------------|-----------------------|------------------------|
|                      | Case/control OR          | Case/control OR (95%CI) |                      |
| Hap1: GCGCG          |                           |                       |                        |
| Diabetes             | 23/23                     | 1.00                  | 8/21                   | 0.28 (0.08-0.97) |
| Without diabetes     | 64/151                    | 1.00                  | 60/134                 | 0.90 (0.53-1.51) |
| Hap2: GCTTG          |                           |                       |                        |
| Diabetes             | 15/29                     | 1.00                  | 17/15                  | 2.79 (0.83-9.43) |
| Without diabetes     | 83/173                    | 1.00                  | 41/112                 | 0.73 (0.42-1.26) |
| Hap3: GCTTA          |                           |                       |                        |
| Diabetes             | 22/34                     | 1.00                  | 9/10                   | 1.17 (0.30-4.51) |
| Without diabetes     | 95/220                    | 1.00                  | 29/65                  | 1.11 (0.57-2.14) |
| Hap4: GCTCA          |                           |                       |                        |
| Diabetes             | 22/36                     | 1.00                  | 9/8                    | 1.91 (0.42-8.78) |
| Without diabetes     | 93/217                    | 1.00                  | 31/68                  | 1.12 (0.59-2.11) |
| Hap5: GTTCG          |                           |                       |                        |
| Diabetes             | 26/27                     | 1.00                  | 5/17                   | 0.50 (0.12-2.09) |
| Without diabetes     | 92/232                    | 1.00                  | 32/53                  | 2.12 (1.13-3.99) |
| Hap6: GCTCG          |                           |                       |                        |
| Diabetes             | 26/39                     | 1.00                  | 5/5                    | 2.50 (0.32-19.61) |
| Without diabetes     | 111/234                   | 1.00                  | 13/51                  | 0.48 (0.21-1.10) |
| Hap7: TCTCG          |                           |                       |                        |
| Diabetes             | 25/41                     | 1.00                  | 6/3                    | 7.15 (0.55-93.39) |
| Without diabetes     | 109/257                   | 1.00                  | 14/28                  | 1.10 (0.48-2.54) |

ApoE ε4 carriers

|                      | Case/control OR          |                                    |                        |
| Hap1: GCGCG          |                           |                                      |                        |
| Diabetes             | 7/3                       | 1.00                                 | 9/3                    | 2.53 (0.19-33.57) |
| Without diabetes     | 52/25                     | 1.00                                 | 39/24                  | 0.64 (0.28-1.48) |
| Hap2: GCTTG          |                           |                                      |                        |
| Diabetes             | 12/4                      | 1.00                                 | 4/2                    | 2.17 (0.13-35.20) |
| Without diabetes     | 48/28                     | 1.00                                 | 43/21                  | 1.04 (0.42-2.57) |
| Hap3: GCTTA          |                           |                                      |                        |
| Diabetes             | 15/6                      | 1.00                                 | 1/0                    | NA                     |
| Without diabetes     | 72/40                     | 1.00                                 | 19/9                   | 1.43 (0.47-4.31) |
| Hap4: GCTCA          |                           |                                      |                        |
| Diabetes             | 9/5                       | 1.00                                 | 7/1                    | NA                     |
| Without diabetes     | 70/41                     | 1.00                                 | 21/8                   | 1.49 (0.48-4.60) |
| Hap5: GTTCG          |                           |                                      |                        |
| Diabetes             | 13/4                      | 1.00                                 | 3/2                    | NA                     |
| Without diabetes     | 80/44                     | 1.00                                 | 11/5                   | 1.48 (0.35-6.26) |
| Hap6: GCTCG          |                           |                                      |                        |
| Diabetes             | 13/4                      | 1.00                                 | 3/2                    | NA                     |
| Without diabetes     | 66/41                     | 1.00                                 | 25/8                   | 2.42 (0.74-7.95) |
| Hap7: TCTCG          |                           |                                      |                        |
| Diabetes             | 12/5                      | 1.00                                 | 4/1                    | NA                     |
| Without diabetes     | 82/39                     | 1.00                                 | 9/10                   | 0.53 (0.16-1.72) |

All models were adjusted for age, sex, and education. Abbreviations: OR, odds ratio; CI, confidence interval; NA, not applicable.
AD using a set of representative htSNPs and their corresponding haplotypes. In this study, 5 htSNPs were selected via a systematic approach and captured over 85% of genetic information in NGFR (estimated by tagSNP program). In contrast, the only prior study [11] assessed 4 NGFR SNPs, which capture only 14% of genetic information in the gene. Second, the sample size of our study is larger than the Italian study (Cozza et al. vs. ours, sporadic AD: 151 vs. 264, controls: 97 vs. 389). In addition, this study has over 90% power to detect an OR of 0.43 for the main effect and 78% power to detect an OR of 0.28 for the interaction between NFGFR and type 2 DM on the risk of AD. Third, no study has assessed this association in Chinese population and identified NGFR SNPs representative for this ethnic group. Last, the use of brain image increased the validity of AD ascertainment and reduced misclassification of disease subtypes.

This study has some limitations. DM status was self-reported and thus may be biased. However, in our questionnaire, this information was further confirmed by asking if there was a previous diagnosis or taking medications for type 2 DM after seeing a doctor. Because DM is a major disease, participants’ recall of DM diagnosis and their awareness of DM should be relatively accurate [45-47]. As a whole, the chance of recall bias was low.

In summary, this study found that NGFR htSNPs and haplotypes were associated with AD risk. Type 2 DM significantly modified the association between NGFR polymorphisms and the risk of AD in ApoE ε4 non-carriers. Although these findings did not reach statistical significance after correction for multiple tests, it is possible that the NFGFR polymorphisms were associated with familial AD. This is because NGFR rs2072446 was associated with a decreased risk of familial AD in the Italian study [11]. Most of sporadic AD cases are ApoE ε4 non-carriers (60%) observed in this and other studies, therefore, our findings shed light on the importance of identifying genetic markers in ApoE ε4 non-carriers. Future large studies are warranted to confirm our findings.

Acknowledgements
Funding for the study was provided by the National Science Council grants NSC 96-2314-B-002-197 and NSC 97-2314-B-002-168-MY3.

Author details
1Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan. 2Department of Neurology, En Chukong Hospital, Taipei, Taiwan. 3Graduate Institute of Physiology, College of Medicine, National Taiwan University, Taipei, Taiwan. 4Research Center for Genes, Environment and Human Health, Taipei, Taiwan. 5Department of Public Health, College of Public Health, National Taiwan University, Taipei, Taiwan. 6Department of Geriatrics and Gerontology, National Taiwan University Hospital, Taipei, Taiwan. 7Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan. 8Department of Laboratory Medicine, En Chukong Hospital, Taipei, Taiwan. 9Center of Neurological Medicine, Cardinal Tien’s Hospital, Taipei, Taiwan. 10Department of Laboratory Medicine, Cardinal Tien’s Hospital, Taipei, Taiwan.

Authors’ contributions
HCC: data analyses and manuscript writing. YS: participant recruitment. LCL: technical review. SYC: data analyses, manuscript writing, and project coordination. All authors have read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 9 November 2011 Accepted: 12 January 2012
Published: 12 January 2012

References
1. Alzheimer’s Disease Facts and Figures. Alzheimer’s & Dementia. 2010 [http://www.alz.org/alzheimers_disease_facts_figures.asp?type=homepage].
2. Dementia sufferer numbers increasing in Taiwan. [http://www.globalaging.org/health/world/2009/dementiasufferer.html].
3. Davies P, Maloney AJ: Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet 1976, 2(8000):1403.
4. Boissiere F, Lehericy S, Strada O, Agid Y, Hirsch EC: Neurotrophin receptors and selective loss of cholinergic neurons in Alzheimer disease. Mol Chem Neuropharmacol 1996, 28(1):219-223.
5. Hefti F, Mash DC: Localization of nerve growth factor receptor in the normal human brain and in Alzheimer’s disease. Neurobiol Aging 1989, 10(1):75-87.
6. Leschky J, Gould E, Butcher LL: Nerve growth factor receptor is associated with cholinergic neurons of the basal forebrain but not the pontomesencephalon. Neuroscience 1989, 30(1):143-152.
7. Liu H, Kermani P, Teng KK, Hempstead BL: p75 and Trk: a two-receptor system. Trends Neurosci 1995, 18(7):321-326.
8. Lad SP, Neet KE, Mufson EJ: Nerve growth factor: structure, function and therapeutic implications for Alzheimer’s disease. Curr Drug Targets CNS Neurolog Disord 2003, 2(9):315-334.
9. Lee R, Kermani P, Teng KK, Hempstead BL: Regulation of cell survival by secreted proteonutrophins. Science 2001, 294(5548):1945-1948.
10. Knowles JK, Rajadas J, Nguyen TV, Yang T, LeMieux MC, Van der Griend L, Ishikawa C, Masca SM, Wyss-Coray T, Longo FM: The p75 neurotrophin receptor promotes amyloid-beta(1-42)-induced neuritic dystrophy in vitro and in vivo. J Neurosci 2009, 29(34):10627-10637.
11. Cozza A, Melissari E, Iacobetti P, Mariotti V, Tedde A, Nacmias B, Conte A, Sottile S, Pellegrini S: SNPs in neurotrophin system genes and Alzheimer’s disease in an Italian population. J Alzheimers Dis 2008, 15(1):61-70.
12. Li ZG, Zhang W, Sima AA: The role of impaired insulin/IGF action in primary diabetic encephalopathy. Brain Res 2005, 1037(1-2):12-24.
13. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM: Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999, 53(9):1937-1942.
14. Fontbonne A, Ber C, Ducimetiere P, Alperovitch A: Changes in cognitive abilities over a 4-year period are unfavorably affected in elderly diabetic subjects: results of the Epidemiology of Vascular Aging Study. Diabetes Care 2001, 24(2):366-370.
15. Janssen J, Laedche T, Paris E, Obren P, Petersen RC, Butler PC: Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 2004, 53(2):474-481.
16. Schuelke M, Mayatepek E, Inter M, Becker M, Pfeiffer E, Speer A, Hubner C, Finch C: Treatment of ataxia in isolated vitamin E deficiency caused by alpha-tocopherol transfer protein deficiency. J Pediatr 1999, 134(2):240-244.
17. Morris J: The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993, 43(11):2412-2414.
18. Catalano A, Chen HH, Redfield MM, Burnett JC: Jr. Natriuretic peptides as regulators of myocardial structure and function: pathophysiological and therapeutic implications. Heart Fail Clin 2006, 2(3):269-276.
19. Burton EJ, Barber R, Mukaeto-Ladinska EB, Robson J, Perry RH, Jaros E, Kalania RN, O’Brien JT. Medial temporal lobe atrophy on MRI differentiates Alzheimer’s disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis. Brain 2009; 132(Pt 11):195–203.

20. Pfeiffer E: A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. J Am Geriatr Soc 1975, 23(10):433.

21. Gabriel SB, Schaffter SF, Nguyen H, Moore JM, Ray J, Blumenstein B, Higgin J, Defelice M, Luchner A, Faggart M et al: The structure of haplotype blocks in the human genome. Science 2002, 296(5570):2225-2229.

22. Chen YC, Giovannucci E, Lazarus R, Kraft P, Ketkar S, Hunter DJ: Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer. Cancer Res 2005, 65(24):11771-11778.

23. Stram DO, Leigh Pearce C, Bresky P, Friedman M, Hirschhorn JN, Altshuler D, Kolonel LN, Henderson BE, Thomas DC: Modeling and E-M estimation of haplotype-specific relative risks from genotype data for a case-control study of unrelated individuals. Hum Hered 2003, 55(4):179-190.

24. Chapman J, Estupinar J, Asherov A, Goldfarb LG: A simple and efficient method for apolipoprotein E genotype determination. Neurology 1996, 46(1):144-145.

25. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 1993, 261(5123):921-923.

26. Chartier-Harlin MC, Parfitt M, Legrain S, Perez-Tur J, Brousseau T, Evans A, Fish SM, Ragan A, Gourlet V, Berr C, Vidal O, Roques P, Gourlet V et al: Apolipoprotein E, epsilon 4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer’s disease: analysis of the 19q13.2 chromosomal region. Hum Mol Genet 1994, 3(4):569-574.

27. Azad NA, Al Bugami M, Loy-English L: Gender differences in dementia risk factors. Gend Med 2007, 4(2):1-12.

28. Schmidt R, Kienbacher E, Benke T, Dal-Bianco P, Delazer M, Ladurner G, Jellinger K, Marksteiner J, Ransmayr G, Schmidt H, Althshuler D, Kolonel LN, Henderson BE, Thomas DC: Modeling and E-M estimation of haplotype-specific relative risks from genotype data for a case-control study of unrelated individuals. Hum Hered 2003, 55(4):179-190.

29. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 1993, 261(5123):921-923.

30. Chartier-Harlin MC, Parfitt M, Legrain S, Perez-Tur J, Brousseau T, Evans A, Fish SM, Ragan A, Gourlet V, Berr C, Vidal O, Roques P, Gourlet V et al: Apolipoprotein E, epsilon 4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer’s disease: analysis of the 19q13.2 chromosomal region. Hum Mol Genet 1994, 3(4):569-574.

31. Azad NA, Al Bugami M, Loy-English L: Gender differences in dementia risk factors. Gend Med 2007, 4(2):1-12.

32. Schmidt R, Kienbacher E, Benke T, Dal-Bianco P, Delazer M, Ladurner G, Jellinger K, Marksteiner J, Ransmayr G, Schmidt H, Althshuler D, Kolonel LN, Henderson BE, Thomas DC: Modeling and E-M estimation of haplotype-specific relative risks from genotype data for a case-control study of unrelated individuals. Hum Hered 2003, 55(4):179-190.

33. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 1993, 261(5123):921-923.

34. Chartier-Harlin MC, Parfitt M, Legrain S, Perez-Tur J, Brousseau T, Evans A, Fish SM, Ragan A, Gourlet V, Berr C, Vidal O, Roques P, Gourlet V et al: Apolipoprotein E, epsilon 4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer’s disease: analysis of the 19q13.2 chromosomal region. Hum Mol Genet 1994, 3(4):569-574.

35. Azad NA, Al Bugami M, Loy-English L: Gender differences in dementia risk factors. Gend Med 2007, 4(2):1-12.

36. Schmidt R, Kienbacher E, Benke T, Dal-Bianco P, Delazer M, Ladurner G, Jellinger K, Marksteiner J, Ransmayr G, Schmidt H, Althshuler D, Kolonel LN, Henderson BE, Thomas DC: Modeling and E-M estimation of haplotype-specific relative risks from genotype data for a case-control study of unrelated individuals. Hum Hered 2003, 55(4):179-190.

37. Perlmuter LC, Singer DE, Nathan DM: Diabetes, hypertension, and age-related neurodegeneration. J Am Geriatr Soc 2000, 48(11):1327-1333.

38. Abbatecola AM, Paolillo G, Lamponi M, Blandinelli S, Lauretani F, Launer L, Ferrucci L: Insulin resistance and executive dysfunction in older persons. J Am Geriatr Soc 2004, 52(10):1713-1718.

39. Luchsinger JA, Tang MX, Shea S, Mayeux R: Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004, 63(7):1187-1192.

40. Young SE, Mainous AG, Camermolla M: Hyperinsulinemia and cognitive decline in a middle-aged cohort. Diabetes Care 2006, 29(12):2688-2693.

41. Messier C, Gagnon M: Cognitive decline associated with dementia and type 2 diabetes: the interplay of risk factors. Diabetologia 2009, 52(12):2471-2474.